A natural health ingredient known as FUCOIDAN has joined our western fight against cancer -native to the cold temperate seas of China, Japan, Korea. According to Memorial Sloan Kettering Cancer Center, "Fucoidan is a complex polysaccharide found in many species of brown seaweed (including Undaria pinnatifida and Cladosiphon okamuranus Tokida).... shown to slow blood clotting. Laboratory studies suggest that it can prevent the growth of cancer cells and has antiviral, neuroprotective, and immune-modulating effects."
In addition to its anticancer & anti-tumor components, Fucoidan has also shown effects as an antioxidant, anti-angiogenic, antiviral, and anticoagulant activities.  These properties have captured the current interest of clinicians determined to produce treatment solutions for the complex symptoms of the CoronaVirus. At the advent of public recognition of the drug REMDESEVIR (a widely popularized drug for its qualities as an immunomodulator), recent news headlines are highlighting major comparisons and competing statements with "the Seaweed extract to out-perform Remdesivir as a Covid inhibitor". Also, Fucoidan has been compared to HEPARIN, an anticoagulant for its chemical composition of sulfated polysaccharide.
REMDESIVIR: Is recognized as the first approved drug to be effective against SARS-CoV-2.  In a clinical study (on 8/6/2020) by The National Institute of Allergy and Infectious Diseases (NIAID)- a branch of the NIH, tests for the efficacy of the antiviral Remdesivir + the interferon Beta-1a is underway a potential COVID-19 treatment. "Laboratory studies suggest... type 1 interferon can inhibit SARS-CoV-2 and two closely related viruses, SARS-CoV and MERS-CoV. In addition, two small randomized controlled trials suggest that treatment with interferon beta may benefit patients with COVID-19." 
First isolated by Dr. Harvey Kylin in 1913 (Uppsala University, Sweden), Fucoidan has been known to come from different species of brown algae and seaweed, carrying different biochemical properties Fucoidan's bioactivity has been linked to its anti-cancer properties including the induction of inflammation through the immune system, oxidative stress and stem cell mobilization.
The anti-cancer property of fucoidan has been demonstrated in vivo and in vitro in different types of cancers. For the Immune System, Fucoidan has been recognized to increase the number of natural killer cells and increase in the number of cytotoxic T-cells. Tests/Trials of fucoidan's effects on dendritic cells showed that the stimulation of CTLs was more effective in fucoidan-treated DCs which exerted a high level of specific lysis of breast cancer cells . In addition, Fucoidan has also been known to carry (immunomodulatory) protective effects against the side effects from chemotherapies or radiation.
(Geographical distribution of Okinawa mozuku.)
Inflammation and immunity play important roles in the development of tumorigenesis . Current epidemiological and preclinical results strongly support an anti-inflammatory approach to treating cancers. Several therapeutic agents targeting cancer-derived inflammatory responses and related signaling molecules, cytokines, transcription factors, and immune cells are being developed and tested [7.5]. Inflammation, cancer recurrence and cancer metastasis have a complicated relationship. Inflammatory responses play important roles in tumor development, including metastasis .
In mid-2018, an oral administration and absorption study of Mozuku fucoidan in 396 Japanese volunteers was performed. . The results showed that fucoidan absorption in humans is extremely low; the fucoidan concentration after oral administration was approximately ten times higher in urine than in serum, confirming the intestinal absorption of Mozuku fucoidan in humans. The results indicated that volunteers living in Okinawa prefecture have the maximum value of urinary fucoidan, significantly higher estimated urinary excretion of fucoidan by place of residence, and significantly higher Mozuku fucoidan consumption habits compared with those living outside Okinawa prefecture. However, the biological mechanisms of fucoidan absorption across the intestinal tract need to be further investigated.
The above results show that fucoidan, whether through basic in vitro to in vivo research studies or clinical trials in humans, has been proven to produce effect of adjuvant therapy on cancer treatment. This allows molecular mechanisms in cancer research to be applied in adjuvant treatment, in line with the pursuit of translational medicine and the mindset of establishing a direct link between basic medical research and clinical application.
In conclusion, understanding the mechanisms underlying the anti-cancer effects of fucoidan, the advantages of combining fucoidan with therapeutic agents in the treatment of cancers, and the pharmacological limitations of fucoidan will aid the development of more informed approaches to treating cancers and may improve current clinical outcomes for cancer patients.
0. 4. Kylin H. Biochemistry of sea algae. HZ Physiol. Chem. 1913;83:171–197. doi: 10.1515/bchm2.19188.8.131.52. [CrossRef] [Google Scholar]
1. Kwak J.Y. Fucoidan as a marine anticancer agent in preclinical development. Mar. Drugs. 2014;12:851–870. doi: 10.3390/md12020851. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
2. Hu Y., Cheng S.C., Chan K.T., Ke Y., Xue B., Sin F.W., Zeng C., Xie Y. Fucoidin enhances dendritic cell-mediated t-cell cytotoxicity against ny-eso-1 expressing human cancer cells. Biochem. Biophys. Res. Commun. 2010;392:329–334. doi: 10.1016/j.bbrc.2010.01.018. [PubMed] [CrossRef] [Google Scholar]
4. Fucoidan and Cancer: A Multifunctional Molecule with Anti-Tumor Potential https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413214/
5. Fucoidan Extracted from Undaria pinnatifida: Source for Nutraceuticals/Functional Foods https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164441/#B4-marinedrugs-16-00321
6. NIH clinical trial testing remdesivir plus interferon beta-1a for COVID-19 treatment begins https://www.nih.gov/news-events/news-releases/nih-clinical-trial-testing-remdesivir-plus-interferon-beta-1a-covid-19-treatment-begins
7. Albrengues J, Shields MA, Ng D, Park CG, Ambrico A, Poindexter ME, Upadhyay P, Uyeminami DL, Pommier A, Küttner V, Bružas E, Maiorino L, Bautista C, Carmona EM, Gimotty PA, Fearon DT, Chang K, Lyons SK, Pinkerton KE, Trotman LC, Goldberg MS, Yeh JT, Egeblad M (2018) Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science 361:1314–1315
7.5 Grivennikov SI, Greten FR, Karin M (2010) Immunity, Inflammation, and Cancer. Cell 140(6):883–899
8. FDA: Frequently Asked Questions on the Emergency Use Authorization for Remdesivir for Certain Hospitalized COVID-19 Patients - https://www.fda.gov/media/137574/download
9. SpringerOpen: https://clintransmed.springeropen.com/articles/10.1186/s40169-019-0234-9 (open access)
10. Kadena K, Tomori M, Iha M, Nagamine T (2018) Absorption study of mozuku fucoidan in japanese volunteers. Mar Drugs 16:254. https://doi.org/10.3390/md16080254
11. https://www.mdpi.com/1660-3397/16/8/254 Posted by Awareness 4aCure at 11:24 AM
Disclaimer & Copyright Notice: Copyright (c) 2021, IntermediaWorx inc. All Rights Reserved. Additional copyrights shared by: The AngioFoundation (501c3) and the publishers of Prevention101.org & The NY Cancer Resource Alliance [NYCRAlliance.org]. Contents in this article are provided publicly for informational purposes within non-commercial use and not for purposes of resale, distribution, commercial display or performance. Unless otherwise indicated on this web based page, no reproduction of any or all materials of this page is allowed without express/written permission from the publishers. Additional permission may be required from third-parties who have provided limited permission for our publishers to use their content, whereas licenses for some of this Content may contain additional terms. When such Content licenses contain additional terms, we will make these terms available to you on those pages (which his incorporated herein by reference).The publishers/producers of this site and its contents such as videos, graphics, text, and other materials published are not intended to be a substitute for professional medical advice, diagnosis, or treatment. For any questions you may have regarding a medical condition, please always seek the advice of your physician or a qualified health provider. Do not postpone or disregard any professional medical advice over something you may have seen or read on this website. If you think you may have a medical emergency, call your doctor or 9-1-1 immediately. This website does not support, endorse or recommend any specific products, tests, physicians, procedures, treatment opinions or other information that may be mentioned on this site. Referencing any content or information seen or published in this website or shared by other visitors of this website is solely at your own risk. The publishers/producers of this Internet web site reserves the right, at its sole discretion, to modify, disable access to, or discontinue, temporarily or permanently, all or any part of this Internet web site or any information contained thereon without liability or notice to you.